DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

46.73 0.63 (1.37%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $46.73 1.37%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $46.40
Previous Close $46.10
Daily Range $46.21 - $46.86
52-Week Range $29.36 - $54.25
Market Cap $6.8B
P/E Ratio -1,536.67
Dividend (Yield) $0.00 (0.0%)
Volume 1,374,997
Average Daily Volume 688,536
Current FY EPS -$0.25

Sector

Healthcare

Industry

Drugs

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

Is Alkermes plc Stock Undervalued?

Strong science and underserved markets can fuel further gains from this delivery-focused biopharma

ALKS Crosses Above Key Moving Average Level

Cramer's Lightning Round - Edwards LifeSciences Is The Hottest Game In Town (9/15/14)

'Mad Money' Lightning Round: Buy, Buy, Buy St Jude Medical

First Week of October 18th Options Trading For Alkermes (ALKS)

Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog

Credit Suisseā€™s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Sp

Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

Alkermes Gains on Aripiprazole Lauroxil NDA Submission - Analyst Blog

Sector Update: Health-Care Shares Flat Pre-Market

Sector Update: Health Care

See More ALKS News...

ALKS's Top Competitors

ALKS $46.73 (1.37%)
Current stock: ALKS
AMGN $144.01 (1.40%)
Current stock: AMGN
GILD $105.96 (0.03%)
Current stock: GILD
BIIB $329.24 (-0.23%)
Current stock: BIIB